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Fbxo7 is a clinically relevant F-box protein, associated with both cancer and Parkinson’s
disease (PD). Additionally, SNPs within FBXO7 are correlated with alterations in red blood
cell parameters. Point mutations within FBXO7 map within speciﬁc functional domains,
including near its F-box domain and its substrate recruiting domains, suggesting that
deﬁciencies in SCFFbxo7/PARK15 ubiquitin ligase activity are mechanistically linked to early-
onset PD. To date, relatively few substrates of the ligase have been identiﬁed. These
include HURP (hepatoma up-regulated protein), whose ubiquitination results in prote-
asome-mediated degradation, and c-IAP1 (inhibitor of apoptosis protein 1), TNF recep-
tor-associated factor 2 (TRAF2), and NRAGE, which are not destabilized as a result of
ubiquitination. None of these substrates have been linked directly to PD, nor has it been
determined whether they would directly engage neuronal cell death pathways. To dis-
cover ubiquitinated substrates of SCFFbxo7 implicated more directly in PD aetiology, we
conducted a high-throughput screen using protein arrays to identify new candidates. A
total of 338 new targets were identiﬁed and from these we validated glycogen synthase
kinase 3β (Gsk3β), which can phosphorylate α-synuclein, and translocase of outer mito-
chondrial membrane 20 (Tomm20), a mitochondrial translocase that, when ubiquitinated,
promotes mitophagy, as SCFFbxo7 substrates both in vitro and in vivo. Ubiquitin chain
restriction analyses revealed that Fbxo7 modiﬁed Gsk3β using K63 linkages. Our results
indicate that Fbxo7 negatively regulates Gsk3β activity, rather than its levels or localiza-
tion. In addition, Fbxo7 ubiquitinated Tomm20, and its levels correlated with Fbxo7
expression, indicating a stabilizing effect. None of the PD-associated mutations in Fbxo7
impaired Tomm20 ubiquitination. Our ﬁndings demonstrate that SCFFbxo7 has an impact
directly on two proteins implicated in pathological processes leading to PD.
Introduction
F-box proteins assemble with Skp1, Cullin 1 and Rbx1 to form SCF-type E3 ubiquitin ligases [1–3].
These enzymes act in a cascade with a ubiquitin-activating enzyme (E1) and a ubiquitin-carrier
enzyme (E2) to mediate the ubiquitination of their substrates, the consequences of which range from
promoting proteasomal degradation to changing the localization or activity of the modiﬁed protein.
Individual substrates are thought to be targeted for ubiquitination by E3 ligases by factors such as
post-translational modiﬁcations (PTMs), such as phosphorylation, glycosylation, or the phase of the
cell cycle and cellular localization of the substrate and/or the ligase [4]. The biological importance of
F-box proteins stems from their involvement in the regulation of many core processes such as cell
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cycle (Fbxl1, Fbxw5, Fbxw7, and Fbxw1), differentiation and development (Fbxw1, Fbxl14, Fbxo11, Fbxo32,
and Fbxw7), cell death (Fbxw1 and Fbxw7), intracellular signaling (Fbxo25), and others (reviewed in ref. [5–8]).
Fbxo7 is a multi-functional F-box protein, with both SCF-dependent and -independent functions that are
capable of impacting on many core cellular processes, and is associated with human diseases (reviewed in ref.
[9]). For example, the effects of Fbxo7 on the cell cycle are independent of its ubiquitin ligase activity and are
mediated instead through its interactions with cell cycle proteins, Cdk6 and p27 [10,11]. Remarkably, Fbxo7’s
functional effects on cell proliferation and transformation, for example, are dependent on cell type. For
example, Fbxo7 overexpression transforms immortalized ﬁbroblasts and imparts tumorigenic properties to p53
null hematopoietic stem and progenitor cells [10,12]. In contrast, in pro-B cells and pro-erythroblasts, Fbxo7
negatively regulates cell proliferation and differentiation [11]. Within other cell types, altered Fbxo7 activity
may be linked to pathological changes. For example, four studies reported on many SNPs in FBXO7 that corre-
lated with changes in human red blood cell traits such as mean cell volume and mean cell hemoglobin, which
are associated with adverse health outcomes such as anemia, cardiovascular diseases, and cancer [13–16].
Recessive mutations in FBXO7, also designated PARK15, have been identiﬁed in patients with phenotypes of
idiopathic Parkinson’s disease (PD) and an early-onset form of PD [17–20]. Pathological point mutations are
located within speciﬁc domains which hint at Fbxo7 function(s) that might be compromised. In addition to its
F-box domain, which enables incorporation into an SCF complex via Skp1 binding, Fbxo7 contains an Ubl
(ubiquitin-like) domain (aa 1–79), which interacts with Parkin and PINK1; a 40 amino acid linker (aa 129–
169), which binds to Cdk6; a dimerization domain (aa 182–325), which enables homo-dimerization and
hetero-dimerization with PI31; and a PRR (proline-rich region) (aa 423–522), which mediates protein–protein
interactions with hepatoma up-regulated protein (HURP) and Cdk6 (reviewed in ref. [9]). One PD-associated
mutation, T22M, lies within the N-terminal Ubl domain and compromises its ability to interact with Parkin
and to promote mitophagy [21]. A second missense mutation R378G abuts the F-box domain and compro-
mises its ability to interact with Skp1 [22]. Finally, a point mutation R498X within the PRR truncates the ﬁnal
24 aa [17]. The loss of interaction with Skp1 and a substrate-interacting domain resulting from the R378G and
R498X mutations suggests that SCFFbxo7-mediated ubiquitination is compromised in PD patients. However, the
identity of critical targets and the functional effect of their ubiquitination are not known.
To date, there are only a handful of ubiquitinated proteins reported for SCFFbxo7. These include HURP/
DLG7 (hepatoma up-regulated protein), a regulator of mitotic spindle assembly, which is up-regulated in hepa-
tocellular carcinoma, colon cancer, breast cancer, and transitional cell carcinoma [23,24]. SCFFbxo7 also pro-
motes ubiquitination of c-IAP1 (inhibitor of apoptosis) and TRAF2 resulting in decreased NF-κB signaling
activity [25,26]. Most recently, NRAGE (neurotrophin receptor-interacting MAGE) was reported to be ubiquiti-
nated by SCFFbxo7, which positively regulated bone morphogenic protein (BMP) signaling [27]. Interestingly,
Fbxo7 increased formation of a BMP receptor–NRAGE–TAK1–TAB1 complex and up-regulated NF-κB activ-
ity. The contrasting effects of Fbxo7 expression on NF-κB signaling may reﬂect cell-type-speciﬁc effects of
Fbxo7 on this pathway, or alternatively, reﬂect the inﬂuence of other signaling inputs, like cellular stresses.
There is a potential relationship between NF-κB signaling, long-term neuroinﬂammation and PD, as suggested,
for example, by the symptoms demonstrated by the c-Rel knockout mouse [28]; however, evidence for the role
of NF-κB signaling in PD remains controversial (as reviewed in ref. [29]).
There are currently no studies that deﬁne ubiquitination substrates for SCFFbxo7 at a proteome-wide scale,
which would greatly assist in clarifying its function(s) in its multiple clinically relevant settings. Given the con-
trasting biological effects of Fbxo7 expression in different cellular environments, we sought to bypass considera-
tions of cell-type speciﬁcity, cell cycle phase, or subcellular localization, which might limit the interaction of
Fbxo7 with its substrates. We undertook an in vitro high-throughput experimental approach utilizing a human
protein microarray that displays ∼9500 individual proteins on a slide, to identify mammalian substrates for ubi-
quitination by SCFFbxo7. This powerful approach has been used to identify substrates for ubiquitin ligases, such
as yeast Rsp5 [30] and human NEDD4/NEDD4L [31], SCFFbxo25 [32], and SMURF1 [33]. Our in vitro ubiqui-
tination screen identiﬁed 338 unique, high-conﬁdence Fbxo7 substrates distributed across different cellular
compartments, and which are involved in many biological processes. To validate this screen, we assessed indi-
vidually the in vitro and in vivo ubiquitination of two candidate proteins, Gsk3β (glycogen synthase kinase 3β)
and Tomm20 (translocase of outer mitochondrial membrane 20). In addition, the type of ubiquitin chain lin-
kages introduced by Fbxo7 onto these substrates was investigated using ubiquitin chain restriction analysis,
[34] and the functional effects of their ubiquitination were tested.
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Experimental materials and methods
Puriﬁcation of SCF complexes
The SCF components such as human inﬂuenza hemagglutinin (HA)-Skp1, Cul1, Myc-Rbx1, and FLAG-Fbxo7
or FLAG-Fbxo7(ΔF-box) were transfected in HEK293T cells by using polyethylenimine. After 48 h of transfec-
tion, the cells were harvested and resuspended in lysis buffer (LB) (25 mM Tris–HCl, pH 7.5, 225 mM KCl and
1% NP-40) containing a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and phosphatase inhibitors
(10 mM NaF and 1 mM Na3VO4). The lysates were incubated with agarose anti-FLAG M2 beads
(Sigma-Aldrich, St. Louis, MO) for 6 h at 4°C with rocking. Beads were washed with LB and the SCF com-
plexes eluted with FLAG elution buffer (300 mg/ml of peptide FLAG in 10 mM HEPES pH 7.9, 225 mM KCl,
1.5 mM MgCl2, and 0.1% NP-40) for 1 h at 4°C with rocking. The eluates were stored in 15% glycerol at −20°C
until use. To evaluate the puriﬁcation of SCF complexes, immunoblotting was performed and probed using
anti-Fbxo7 (ABN1038, Merck Millipore, Watford, UK), anti-HA (Abcam, Cambridge, UK), anti-Gsk3β (Santa
Cruz Biotechnologies, CA, USA), anti-Tomm20 (Abcam, Cambridge, UK), or anti-myc (Cell Signaling
Technologies, MA, USA). The concentration of the complexes was determined against known concentrations
of BSA by Coomassie blue staining of the gel. The densitometry of the bands was determined by ImageJ.
In vitro ubiquitination assays
The plasmids encoding human Gsk3β-HA and Tomm20 were purchased from Addgene (14 753 and 40 291,
respectively). Human cIAP-1-myc was kindly provided by Dr Yasuko Matsuzawa (Sanford-Burnhan Medical
Research Institute, La Jolla, CA, USA). Tomm20 was cloned into pcDNA3 in fusion with HA at the
C-terminus. cIAP was truncated (183–570) and cloned in fusion with HA at the C-terminus. The substrates
cIAP-1(183–570)-HA, Gsk3β-HA, and Tomm20-HA were produced by in vitro transcription/translation (IVT),
and the crude programmed reticulocyte lysates were added to in vitro ubiquitination reactions. For the ubiquiti-
nation reactions, puriﬁed SCF complexes were used at the indicated concentrations in combination with ubiqui-
tin mix [ubiquitination buffer, E1(100 nM), E2(500 nM), biotin-ubiquitin (20 mM), Mg-ATP (2 mM; Boston
Biochem)], and the puriﬁed substrates and incubated for 90 min at 30°C. Proteins were resolved by SDS–PAGE
and immunoblotting was performed using anti-Gsk3β, anti-Tomm20, or anti-HA antibodies. To determine
which E2(s) enabled SCFFbxo7 ligase activity, an in vitro E2 screening with 10 different E2 enzymes, each at
500 nM was performed. Auto-ubiquitination was observed with UBE2D1 (UbcH5a), UBE2D2 (UbcH5b), and
UBE2D3 (UbcH5c; Supplementary Figure S1), and UBE2D1 (UbcH5a) was used in further experiments.
Reactions were resolved by SDS–PAGE and detected by probing with streptavidin–HRP (Thermo Pierce, MA,
USA).
Analysis of ligases
Samples were resolved ∼1 cm into a pre-cast SDS–polyacrylamide gel, and the entire lane was excised and cut
into four equal slices. Proteins were reduced and alkylated, then digested in-gel using trypsin. The resulting
peptides were analyzed by LC–MS/MS using an Orbitrap XL (Thermo) coupled to a nanoAcquity UPLC
(Waters). Data were acquired in a DDA fashion with MS/MS in the LTQ triggered at 1000 counts. Raw ﬁles
were converted into mzML using MSconvert (ProteoWizard) and submitted to MASCOT 2.3.0 to search a
human Uniprot database (20 264 entries, downloaded on 09 June 14). Carbamidomethyl cysteine was set as a
ﬁxed modiﬁcation with oxidized methionine and deamidation of asparagine and glutamine as potential variable
modiﬁcations. Peptide and protein validation were performed using Scaffold 4.3.2. Peptides required a
minimum of 95% probability and proteins required a minimum of 90% probability and two peptides in order
to be counted.
In vitro ubiquitination assays of protein arrays
Protoarray® v5.0 was obtained from Life Technologies (catalog number PAH0525101). Supplementary Table S1
contains an Excel ﬁle of Protoarray® v5.0 protein content. Protocols were followed according to the manufac-
turer’s instructions (Protoarray® v5.0, Invitrogen, MA, USA). Slides were incubated in Protoarray® Synthetic
Block for 1 h at 4°C with shaking at 50 rpm. During this time, reactions were prepared in a volume of 120 ml
as follows: 25 or 50 nM of the puriﬁed SCFFbxo7 or Fbxo7(ΔF-box) in combination with ubiquitin mix [E1
(100 nM), UbcH5a (500 nM), Mg-ATP (2 mM), and biotin-ubiquitin 0.1 mg/ml in ubiquitination buffer;
Boston Biochem]. The slides were washed with assay buffer (AB; 50 mM Tris, pH 7.5, 50 mM NaCl, 5 mM
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MgSO4, 0.1% Tween 20, 1% BSA, and 1 mM DTT) and 110 ml of the reaction was added to the slide and over-
laid with a coverslip followed by incubation for 1.5 h at 30°C in a humidiﬁed chamber. Slides were washed in
0.5% SDS and AB and then incubated with 1 mg/ml of streptavidin–AlexaFluor 647 for 45 min at 4°C with
shaking. The arrays were washed with AB, once with distilled water, and ﬁnally dried by centrifugation at
1000 × g for 2 min, before being scanned on a GenePix Personal 4100A (Axon–Molecular Devices).
Data acquisition and analysis
Software used for Protoarray® image acquisition was GenePix Pro 4.1 (Molecular Devices). The experimental
design comprised two biological replicates [25 or 50 nM ligase of wild type (WT) or mutant F-box protein, ΔF]
with two intraslide technical replicates. Each slide has 3004 negative control spots (Supplementary Table S2)
and 576 positive control spots (Supplementary Table S3).
The intensity value of each array feature was considered as the average raw intensity of all pixels in the
delimited spot region minus the median intensity of pixels immediately surrounding the spot region (local
background). Background-subtracted intensities were subjected to normalization to make them directly com-
parable among different Protoarray® slides (replicates and conditions). Assuming that the
manufacturer-produced positive controls should present the same theoretical intensities among replicates, their
background-corrected values were obtained and a single centering (normalization) value per slide was deﬁned
as the average of all known positive control spots. An interslide, study-wide overall positive control value was
obtained by averaging all the intraslide centering/normalization factors. Finally, all array features had their
background-subtracted intensities corrected by this overall factor to end up with comparable normalized inten-
sities (IWT,25 nM, IWT,50 nM, IΔF,25 nM, and IΔF,50 nM).
To determine spots with statistically signiﬁcant signals, we used all the negative control spots to estimate
non-parametrically the null density distribution (NC) for each slide using a Gaussian kernel density estimator
[35]. The intensity value that encompasses the vast majority of null probability mass was chosen as cutoff (c)
for each slide: P(NC > c) = 0.005. This yielded four cutoff values: cWT,25 nM; cWT,50 nM; cΔF,25 nM, and cΔF,50 nM.
Selected spots presented intensities IWT > cWT and IΔF < cΔF for each concentration and log fold change [FC =
log2(IWT/IΔF)] greater than 5-fold: log2(IWT/IΔF) > log2(5). To increase stringency, only proteins which met
these criteria simultaneously on both concentrations were deﬁned as possible substrates. Mean FC values of
possible substrates were calculated and used to rank the proteins (Supplementary Table S4).
The selected list of proteins was subjected to Gene Enrichment analysis using DAVID Bioinformatics
Resources v6.7 [36] using Protoarray® v5.0 content (Supplementary Table S1) or the human proteome as the
background. DAVID’s P-values up to 0.05 were considered signiﬁcant (Supplementary Table S4).
In vivo ubiquitination assays and co-immunoprecipitation assays
HEK293T cells were transfected with empty vector, FLAG-Fbxo7 or FLAG-Fbxo7-ΔF-box, or truncated
FLAG-Fbxo7 alleles where indicated, in combination with Gsk3β-HA or Tomm20-HA, with or without
ubiquitin-6xHis-myc. Where indicated, cells were treated with 10 mM of MG132 prior to lysis with LB for
30 min on ice. Cells were centrifuged and supernatants were subjected to immunoprecipitation (IP) with
agarose-anti-HA or agarose-anti-FLAG. The proteins were eluted by Laemmli buffer and the eluates were
resolved by SDS–PAGE. The ubiquitinated proteins were visualized using antibodies to HA, the substrates, or
anti-myc antibody.
In vitro binding assays
HEK293T cells were transfected with empty vector or various FLAG-Fbxo7 truncation mutants. Cells were
lysed in NETN lysis buffer [NB; 10 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, and 0.2% NP-40 con-
taining a protease inhibitor cocktail and phosphatase inhibitors (10 mM NaF and 1 mM Na3VO4)], and clari-
ﬁed lysates were subjected to IP with anti-FLAG antibodies immobilized on agarose beads. Gsk3β-HA protein
was IP from transfected HEK293T cells by anti-HA antibodies immobilized on agarose beads and eluted using
HA peptide. Gsk3β-HA protein was added to immobilized FLAG-Fbxo7 proteins and rotated for 3 h at 4°C.
Beads were washed twice in NB and twice in RIPA buffer, then eluted by Laemmli buffer and the eluates
resolved by SDS–PAGE.
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Fbxo7 protein knockdown
Cells were infected with miR30-based retroviruses encoding independent human FBXO7-speciﬁc shRNAs and
selected using puromycin (2 μg/ml), as described previously [11]. Transient knockdown (KD) of Fbxo7 was
performed by transfecting dsRNA targeting Fbxo7 into cells using Effectene (Invitrogen) as described previ-
ously [10].
Gsk3β activity reporter
The Gsk3β reporter pCS2-GFP-Gsk3-MAPK and mutant version pCS2-GFP-Gsk3mut-MAPK described in ref.
[37] were purchased from Addgene (29 689 and 29 690, respectively). U2OS cells were transfected with empty
vector, FLAG-Fbxo7, or FLAG-Fbxo7(ΔF-box) and 24 h later transfected with pCS2-GFP-Gsk3-MAPK or
pCS2-GFP-Gsk3mut-MAPK, in quadruplicate. After a further 24 h, cells were trypsinized and analyzed by ﬂow
cytometry using a Cytek analyzer. The GFP mean ﬂuorescence intensity was determined and levels were
expressed as a percentage of the mutant GFP-Gsk3mut-MAPK-expressing cells.
Ubiquitin chain restriction analysis
Ubiquitin chain restriction (UbiCRest) analyses were performed as described recently [34]. In vivo expressed
substrates were IP from HEK293T cells transfected with FLAG-Fbxo7 and the tagged-HA substrates using
agarose-anti-HA. Cell lysates were obtained as mentioned above and the in vivo polyubiquitinated substrates
were eluted by HA peptide at 300 mg/ml in FLAG elution buffer and stored at −80°C. Deubiquitinating
enzymes (DUBs) were diluted with 2× dilution buffer (50 mM Tris, pH 7.4, 300 mM NaCl, and 20 mM DTT)
and added to the samples for 30 min at 37°C, and reactions were stopped by Laemmli buffer. Samples were
run on SDS–PAGE, and the blots were probed for anti-polyubiquitin (Santa Cruz Biotechnologies, CA, USA).
Immunoﬂuorescence
U2OS cells were plated onto glass coverslips, transfected with FLAG-Fbxo7, and 24 h later ﬁxed in 4% parafor-
maldehyde in PBS for 15 min. Cells were permeabilized in 0.2% Triton X-100 in PBS, blocked for 1 h in 10%
donkey serum, and incubated overnight with anti-FLAG and anti-Gsk3β antibodies. Cells were repeatedly
washed in PBS, incubated with anti-rabbit AlexaFluor 488 and anti-mouse AlexaFluor 647 for 1 h, washed
again, and then counterstained with Hoechst 33342 to visualize nuclei. Cells were visualized using a Zeiss
ApoTome microscope.
Luciferase assays
U20S cells, seeded at 5000 cells per well of a 96-well plate, were transfected in quintuplicate with 1.5 ng
pCMV-Renilla luciferase control plasmid, 75 ng minimal promotor ﬁreﬂy luciferase (pTA-luc) or LEF/TCF
responsive ﬁreﬂy luciferase reporters (TOP-FLASH), and 75 ng empty, FLAG-Fbxo7 or FLAG-Fbxo7(ΔF-box)
vectors. Where stated, cells were treated after 24 h with 50 mM LiCl or NaCl and 24 h later, luciferase levels
were assayed using the Dual Glo luciferase assay system (Promega, Southampton, UK).
Statistical analysis
Statistical differences in normalized protein levels in shRNA lines were compared with vector control levels
using Student’s t-tests. For Gsk3β reporter assays, normalized data were analyzed by one-way ANOVA, with
a post hoc Dunnett’s multiple comparisons test to determine statistical signiﬁcance compared with control
cells. For luciferase assays, one-way ANOVA with a post hoc Tukey’s multiple comparisons test was used to
determine differences between samples.
Results
Puriﬁed SCFFbxo7 complexes are active in vitro
SCF complexes were puriﬁed from mammalian HEK293T cells using mild conditions to maintain activity and
structure. WT Fbxo7, but not a mutant with a deletion of the F-box domain (denoted ΔF-box, lacking amino
acids 335–367), co-puriﬁed with other SCF components: Skp1, Cullin1, and Rbx1 (Figure 1A,B). To test for
ligase activity, we performed in vitro ubiquitination assays using SCFFbxo7 or the mutant Fbxo7(ΔF-box) in con-
junction with both E1 and E2 enzymes. We found UBE2D1 (UbcH5a), UBE2D2 (UbcH5b), UBE2D3
(UbcH5c), and UBE2E1 (UbcH6), all promoted robust levels of auto-ubiquitination in a screen of E2 enzymes
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(Supplementary Figure S1A,B). To test the ability of SCFFbxo7 to ubiquitinate one of its known substrates, we
used cIAP-1 [25,26]. This protein contains a RING box domain that can bind independently to E2 enzymes,
promoting auto-ubiquitination. As this would obscure the ubiquitination signal generated by SCFFbxo7, this
RING domain was deleted, creating cIAP-1(183–570)-HA, for these assays. cIAP-1(183–570)-HA was synthe-
sized by IVT using reticulocyte lysates, and the programmed lysates were added to in vitro ubiquitination reac-
tions. A smear of higher molecular weight (MW) ubiquitinated species of cIAP-1, which intensiﬁed with
increasing concentration of ligase, was seen in the presence of the WT SCFFbxo7, but not mutant Fbxo7
(ΔF-box; Figure 1C). These experiments established that the puriﬁed SCFFbxo7 ligase showed robust ligase activ-
ity and could ubiquitinate itself and one of its known substrates.
In addition to probing for known subunits of an SCF-type E3 ligase (Figure 1B), we also conducted an
unbiased mass spectrometry (MS)-based screen on the puriﬁed WT ligase and the mutant Fbxo7(ΔF-box).
Alongside expected SCF components, NEDD8, two proteasome subunits (PSMB3 and PSMB6), EIF4A2, FBL,
HDLBP, and DNAJB6, appeared exclusively associated with SCFFbxo7 and not the vector control or the mutant
F-box protein made from transfection with Fbxo7(ΔF-box; Supplementary Table S4). A longer list of 107 pro-
teins that interacted with both the WT SCFFbxo7 ligases and the mutant Fbxo7 protein, included the prote-
asome inhibitor, PI31, a previously identiﬁed dimerization partner of Fbxo7 [38]. The association of PI31 with
the ligases was conﬁrmed by immunoblotting, where an Fbxo7(V253E) mutant that prevents binding to PI31
served as a negative control (Figure 1D). Analysis of the longer list using KEGG databases for data enrichment
identiﬁed proteins from the ribosome, proteasome, and spliceosome as being signiﬁcantly represented
(Supplementary Table S4).
Identiﬁcation of novel SCFFbxo7 substrates using a protein array
We next optimized the SCF E3 ligase to perform a large-scale in vitro ubiquitination experiment using a
protein microarray. The commercially available Protoarray® v5.0 (Invitrogen) contained over 9000 unique, full-
length native proteins puriﬁed and spotted in duplicate under non-denaturing conditions onto a nitrocellulose
slide. Ligase activity was ﬁrst titrated, and a 50 nM concentration, which demonstrated robust auto-
ubiquitination activity, was chosen for use on the array (Supplementary Figure S1C). Ligase (25 nM) was used
in a replicate experiment, where more overall signal was seen on the array with the WT than the mutant ligase
(Figure 2A,B). Overviews of the experimental design (Figure 2A) and the data analysis (Supplementary
Figure S2, Materials and Methods) are provided. To increase the stringency of our screen, only proteins which
met deﬁned criteria for statistically signiﬁcant intensities at both 25 and 50 nM of ligase were categorized as
possible substrates. This analysis yielded 338 unique proteins as substrates of SCFFbxo7 (Supplementary
Table S5).
Candidate substrates were next grouped in accordance with their cellular compartment and their biological
pathway using the Gene Onthology and KEGG databases for data enrichment (Supplementary Table S5)
[39,40]. Forty-six candidate substrates were localized to the nuclear lumen, 39 to the cytosol, 13 to the ribo-
some, and 10 to the microtubule-organizing centre. This wide distribution pattern of candidate substrates is in
agreement with the reported localization of Fbxo7 [10,22], and with the analyses of Fbxo7 ligases
(Supplementary Table S4). Consistent with the presence of a mitochondrial-targeting sequence (MTS) at the
N-terminus of Fbxo7, 29 candidates were localized to mitochondria, where Fbxo7 interacts with Parkin and
PINK1 to mediate stress-induced mitophagy [21]. Such candidates represent potential Fbxo7 substrates that
may be important for this process. In addition, although PINK1 is present on the Protoarray® (Supplementary
Table S1), it was not ubiquitinated by SCFFbxo7, suggesting that their reported interaction does not result in
PINK1 ubiquitination. An analysis of the substrates using Enrichment by Biological Process indicated that
Fbxo7 ubiquitinates multiple proteins that have an impact on ErbB2 (10 substrates), Wnt (10 substrates), and
MAPK (13 substrates) signalling, ribosomes (9 substrates), axonal guidance (10 substrates), and pathways in
cancer (16 substrates). We reported that Fbxo7 regulated cyclin D/Cdk6/p27 complexes which transformed
cells, via an ubiquitin-independent mechanism [10], and in agreement with this, cyclin D3, Cdk6, and p27
were present on the Protoarray® v5.0 (Supplementary Table S1), but not ubiquitinated. Our dataset further indi-
cates that SCFFbxo7 also ubiquitinates proteins important in cancer progression. With regard to concordance
with known SCFFbxo7 substrates, cIAP-1, HURP, and NRAGE were not present on the protein arrays, and
although TRAF2 was, it did not make the ﬁnal list of substrates due to high levels of signal with the negative
control Fbxo7(ΔF-box). We speculate that as TRAF2 is also an E3 ligase, it catalyzed auto-ubiquitination in the
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presence of the ubiquitin mix used in this experiment, hence the high background observed in the negative
control.
These data demonstrate the robust ligase activity of the SCFFbxo7 ligase and its potential to ubiquitinate a
large number of proteins. Importantly, there was no overlap between the SCFFbxo7 substrates with those identi-
ﬁed in a previously reported SCFFbxo25 Protoarray® screen [41], arguing that this methodology identiﬁes speciﬁc
candidate substrates for individual SCF-type E3 ligases.
Figure 1. Fbxo7, but not a mutant version Fbxo7(ΔF-box), forms an active SCF complex.
(A) Puriﬁed SCF ligases resolved by SDS–PAGE and visualized with Coomassie brilliant blue stain (n = 3). (B) Immunoblots for
components of SCF holoenzyme that co-immunoprecipitate with FLAG-Fbxo7 or FLAG-Fbxo7-ΔF-box (n = 2). (C) Titration of
the ligase activity of puriﬁed SCFFbxo7 complexes or mutant Fbxo7(ΔF-box) protein on cIAP-1(183–570)-HA. A concentration
gradient (5, 10, 20, and 40 nM) of SCFFbxo7 or Fbxo7(ΔF-box) protein was used for in vitro ubiquitination assays in combination
with ubiquitin mix (ubiquitin buffer, E1, UBE2D1, and ATP) and puriﬁed cIAP-1(183–570). Membranes were probed with anti-HA
antibodies to visualize the ubiquitination proﬁle and anti-FLAG antibodies to evaluate the amount of E3 ligase (n = 2).
(D) Immunoblot for proteins that co-immunoprecipitate with FLAG-tagged SCF Fbxo7 ligases (WT, ΔF-box, or V253E).
© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) 3569
Biochemical Journal (2016) 473 3563–3580
DOI: 10.1042/BCJ20160387
Gsk3β and Tomm20 were ubiquitinated in vitro and in vivo by SCFFbxo7
One caveat inherent in using protein arrays is that the full-length proteins spotted on the arrays are puriﬁed
from insect cells in fusion with both His and GST tags, which may affect ubiquitination. Also, these proteins
would lack the posited PTMs and/or cofactors, which may be needed for ligase recruitment within cells. We
therefore wished to retest our ﬁndings from the arrays using independent methodologies. To take this forward,
we selected Gsk3β, ranked 38th, and Tomm20, ranked 44th (Supplementary Table S5), because of the existing
literature arguing that they act within pathways that are potentially involved in the pathobiology of PD, and
because inhibitors of these pathways are being pursued as potential therapeutics [21,42–47]. Their ubiquitina-
tion signal on the arrays is shown in Figure 2B. We produced these potential substrates by in vitro transcrip-
tion/translation in reticulocyte lysates using plasmids encoding C-terminally HA-tagged substrates, Gsk3β-HA
or Tomm20-HA, and used these programmed lysates for in vitro ubiquitination assays (Figure 3A,B and
Supplementary Figure S3A,C). We also used puriﬁed Gsk3β-HA or Tomm20-HA isolated by immunoprecipita-
tion from cells and eluated with HA peptide as the substrates for in vitro ubiquitination assays (Supplementary
Figure S3B,D). In the case of Gsk3β, a smear of higher MW bands was seen in crude reticulocyte lysates when
no exogenous ligase was added to the reaction, suggesting that Gsk3β modiﬁcation occurred in reticulocyte
Figure 2. Identiﬁcation of new Fbxo7 ubiquitinated substrates using protein arrays.
(A) Schematic of the experimental design. Two concentrations of SCFFbxo7 or Fbxo7(ΔF-box) protein were used for the
ubiquitination of Protoarrays®. Unique substrates were grouped according to the Gene Ontology Cell Compartment or
Biological Process through the use of Cytoscape (plugin ClueGO+CluePedia; Supplementary Table S4). (B) Both
concentrations of the SCFFbxo7, but not Fbxo7(ΔF-box) protein, promoted ubiquitination of Gsk3β and Tomm20. Quantiﬁcation
of the ﬂuorescence intensity of individual spots.
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lysates (Figure 3A and Supplementary Figure S3A). However, there was an increased intensity of higher MW
bands in the presence of WT SCFFbxo7 ligase, which was dependent on the F-box domain (Figure 3A and
Supplementary Figure S3A,B). For Tomm20, the addition of WT SCFFbxo7 ligase promoted discrete laddering,
suggesting mono- or multi-mono-ubiquitination, and was also dependent on the F-box domain of Fbxo7
(Figure 3B, arrows). In addition, higher MW bands, dependent on Fbxo7 ligase activity, were also detectable
using antibodies to Tomm20 (Supplementary Figure S3C,D, arrows). Taken together, these data support the
idea that SCFFbxo7 catalyzed ubiquitination of these proteins.
To further test whether these candidate targets are substrates for SCFFbxo7, we carried out ubiquitination
assays in HEK293T cells co-transfected with plasmids encoding C-terminally HA-tagged substrates including
Gsk3β-HA or Tomm20-HA and N-terminally FLAG-tagged Fbxo7 or Fbxo7(ΔF-box). Substrates were IP via
their HA tag, and immunoblotted with antibodies to the protein (Gsk3β or Tomm20; Figure 3C,D). In the
samples co-transfected with WT Fbxo7, a smear of higher MW proteins was seen for Gsk3β (Figure 3C), while
discrete laddering was observed for Tomm20 (Figure 3D). Similar results were obtained when experiments
were performed with endogenous ubiquitin (Supplementary Figure S3E,F). In addition, in in vivo ubiquitina-
tion assays performed with exogenous myc-tagged ubiquitin, Tomm20 showed discrete laddering, and both
proteins showed robust smears of high-MW polyubiquitinated proteins over 100 kDa (Supplementary
Figure S3G,H). These data support the idea that Fbxo7 promoted ubiquitination of both Gsk3β and Tomm20,
and taken together, with the in vitro ubiquitination assays indicate that these two candidates identiﬁed on the
protein arrays are ubiquitinated substrates of SCFFbxo7.
The N-terminus of Fbxo7 can mediate an interaction with Gsk3β
To determine the region within Fbxo7 required for interacting with these substrates in cells,
co-immunoprecipitation assays were conducted. HEK293T cells were co-transfected with plasmids encoding
C-terminally HA-tagged Gsk3β and various N-terminally FLAG-tagged Fbxo7 constructs: WT or Fbxo7 con-
structs wherein the Ubl domain (1–88), a linker region (89–128), the PRR (399–522), or the last 24 aa at the
C-terminus (R498X) was deleted either singly or in combination. The R498X mutation is a naturally occurring
pathogenic mutation causing an early-onset PD. For Gsk3β, the loss of either the C-terminal 24 aa (R498X) or
the PRR (1–398) did not substantially affect binding (Figure 4A). Loss of the N-terminal Ubl domain, as tested
with the 89–522 construct, also did not affect Fbxo7 interaction with Gsk3β. However, loss of both the Ubl
domain and the linker, as seen with a 129–522 construct, ablated their interaction. At the Fbxo7 C-terminus,
loss of the PRR alone, 1–398, weakened binding, but the additional loss of the Ubl domain, as tested with the
89–398 construct, ablated Gsk3β binding altogether. These data suggest that the PRR, together with the Ubl/
linker sequences, contributes to the interaction of Fbxo7 with Gsk3β in cells, but is not sufﬁcient to mediate
binding (Figure 4A). These experiments indicate multiple binding sites and/or a bipartite interaction for Gsk3β
with Fbxo7. These interaction experiments are summarized in Figure 4B. To further validate the binding sites
of Gsk3β on Fbxo7, we performed in vitro binding assays using FLAG-Fbxo7 deletion mutants immunopuriﬁed
from cells and immobilized on agarose, in binding assays with puriﬁed Gsk3β (Figure 4C). In support of the in
vivo co-immunoprecipitation studies, Fbxo7 constructs lacking the ﬁrst 129 amino acids, deleting the Ubl and
linker of Fbxo7 were unable to interact with Gsk3β. Fbxo7 1–398 lacking only the PRR could still bind to
Gsk3β, as could ΔF-box in this in vitro setting. To test this further, we created a ligase lacking the N-terminal
128 amino acids for its ability to ubiquitinate Gsk3β. We found that SCFFbxo7(129–522) was an E3 ubiquitin
ligase with equivalent activity to SCFFbxo7 (Supplementary Figure S4A), which showed reduced activity against
Gsk3β tested in in vitro ubiquitination assays (Figure 4D). These data argue for the N-terminus of Fbxo7 being
the domain through which Gsk3β can be recruited for ubiquitination.
Similar experiments to map the interaction of Fbxo7 with Tomm20 were conducted in cells (Figure 4E) and
by in vitro binding assays, although the latter were unsuccessful. In cells, the interaction of Tomm20 with
Fbxo7 was substantially weakened when the N-terminus was deleted, see 89–522 and 129–522, suggesting that
amino acids 1–128 also mediated the interaction of Fbxo7 and Tomm20. However, unlike Gsk3β, which is
reported to localize in the cytosol, nucleus, and mitochondria, Tomm20 is part of a tranlocation complex and
resident in the outer membrane of mitochondria. Therefore, an alternative explaination for this loss of binding
could be the deletion of the MTS of Fbxo7, which lies at the start of isoform 1 (Figure 4B) and is essential for
its recruitment to mitochondria [21]. To test this directly, an in vitro ubiquitination assay with SCFFbxo7(129–522)
against Tomm20 was performed and showed that the ligase lacking the N-terminus of Fbxo7 was still able to
mono-ubiquitinate Tomm20, and that there was only minor loss of ubiqutinated higher MW species
© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) 3571
Biochemical Journal (2016) 473 3563–3580
DOI: 10.1042/BCJ20160387
(Figure 4F). These data argue that other sites downstream of amino acid 128 in Fbxo7 bind to Tomm20.
Deletion of the PRR at the C-terminus of the Fbxo7 (1–398) did not compromise binding to Tomm20, but
suprisingly, deletion of the PRR restored Tomm20 binding to Fbxo7 lacking the MTS/Ubl domain (Figure 4,
Figure 3. Fbxo7 promotes ubiquitination of Gsk3β and Tomm20 in vitro and in cells.
In vitro ubiquitination reactions contained puriﬁed SCFFbxo7 ligase or Fbxo7(ΔF-box) protein and ubiquitin mix (E1, UBE2D1,
ubiquitin, and ATP) in combination with HA-tagged substrates Gsk3β (n = 2) (A) or Tomm20 (n = 2) (B). The proteins were
resolved by SDS–PAGE, and immunoblots were performed with the indicated antibodies. (C and D) HEK293T cells were
transfected with the indicated plasmids and the substrates were IP with anti-HA beads; Gsk3β (n = 3) (C) and Tomm20 (n = 3)
(D). Proteins were separated by SDS–PAGE, and immunoblots were probed with antibodies to the substrates.
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Figure 4. The N-terminus of Fbxo7 mediates its interaction with Gsk3β.
(A) HEK293T cells were transfected with the indicated FLAG-Fbxo7 plasmids and Gsk3β-HA and the lysates were IP with
anti-FLAG beads. Proteins were resolved by SDS–PAGE, and immunoblots were probed with the indicated antibodies.
(B) Summary of the interaction mapping for Gsk3β and Tomm20 with various Fbxo7 constructs. (C) In vitro binding assays
using immunopuriﬁed and eluted Gsk3β-HA protein added to various Fbxo7 proteins lacking N- and C-terminal domains
immobilized on anti-FLAG antibodies on agarose. (D) In vitro ubiquitination assay using an SCFFbxo7(129–522) ligase lacking the
N-terminus against immunopuriﬁed and eluted Gsk3β-HA protein as the substrate. (E) HEK293T cells were transfected with the
indicated FLAG-Fbxo7 plasmids and Tomm20-HA and the lysates were IP with anti-FLAG beads, as in (A). (F) In vitro
ubiquitination assay using an SCFFbxo7(129–522) ligase lacking the N-terminus against immunopuriﬁed and eluted Tomm20-HA
protein as the substrate. (G) In vivo co-immunoprecipitation assays conducted as in (E).
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compare 89–522 binding with 89–398). Potential reasons for this include that the PRR inhibits Fbxo7 inter-
action with Tomm20 or the smaller 89–398 construct can localize to the mitochondria. Combined, these data
indicate that sequences between 89 and 398 of Fbxo7 can bind to Tomm20 in cells. These sequences include
the F-box domain (335–372), and we also noted a diminished interaction of Tomm20 with an Fbxo7 construct
lacking the F-box domain similar to Gsk3β (Figure 4A,E). However, this was likely to be due to a change in the
localization of Fbxo7 as a result of a deletion of an NES embedded within the ﬁrst helix of the F-box domain
[22]. We previously demonstrated that the NES of Fbxo7 is important for its cell cycle-dependent cytoplasmic/
nuclear shuttling, and if mutated, Fbxo7 becomes a predominantly nuclear protein. To test whether the ΔF-box
mutant does not interact with Tomm20 because of its localization to the nucleus, we utilized an Fbxo7 quadru-
ple point mutant, called H1, which mutates the F-box domain such that it does not bind to Skp1 but leaves a
functional NES. The H1 mutant localizes similarly to WT, predominantly cytoplasmic with nuclear shuttling
[22]. We directly compared the H1 mutant with the ΔF-box mutant for their interaction with Tomm20 using
co-immunoprecipitation studies, and found the H1 mutant can bind to Tomm20, whereas the ΔF-box mutant
does not (Figure 4G), supporting the nuclear localization of the NES/ΔF-box mutant is the likely cause for the
lack of interaction with Tomm20. Both mutants do not bind to Skp1, which also indicates that Fbxo7 can bind
to Tomm20 independent of it being part of an E3 ligase.
SCFFbxo7 promotes non-degradative chain formation on Gsk3β and Tomm20
The type of polyubiquitin chain linkages catalyzed by an E3 ligase on a substrate induces different functional
consequences [48]. To investigate the types of ubiquitin chains ligated by SCFFbxo7 onto Gsk3β, we carried out
UbiCRest analyses by using DUBs as described in ref. [34]. The source of the ubiquitinated protein used in
DUB assays was obtained by immunoprecipitating Gsk3β-HA from cells also transfected with Fbxo7 as in
Figure 3A, where Fbxo7 expression enhanced a smear of ubiquitination. Ubiquitinated Gsk3β was subjected to
cleavage using a panel of DUBs, including as a positive control, USP21, a non-speciﬁc DUB which cleaves all
types of ubiquitin chains (Figure 5A). Only increasing amounts of the K63-speciﬁc OTUD1 concentration
diminished the intensity of the smear of polyubiquitinated Gsk3β (Figure 5A, lanes 6 and 7), indicating that
Fbxo7 catalyzed predominantly K63-linked ubiquitin chains. To independently test for the presence of
Fbxo7-enhanced K63 chains on Gsk3β, HEK293T cells were co-transfected with Gsk3β-HA and Fbxo7 or
ΔF-box domain. Immunoprecipitates of Gsk3β-HA were probed for the presence of K63 chains, and these were
detected when Fbxo7, but not ΔF-box, was overexpressed (Figure 5B).
To test the effect of SCFFbxo7 ubiquitination on Gsk3β and Tomm20, their total levels were assayed by
immunoblotting of HEK293T cell lysates where constitutive knockdown (KD) of Fbxo7 expression was
achieved by stable expression of two independent short hairpin miRNA constructs. Consistent with the identiﬁ-
cation of mainly K63 polyubiquitination by SCFFbxo7 from UbiCRest analyses, reducing Fbxo7 expression did
not alter Gsk3β levels (Figure 5C). These results were also conﬁrmed by similar experiments in SHSY-5Y KD
cells (data not shown) and in experiments where cells were transiently transfected with dsRNA targeting Fbxo7
in U2OS cells (Supplementary Figure S4B). These ﬁndings suggest that ubiquitination may modulate its local-
ization or function. Gsk3β is an upstream regulator of β-catenin, which has roles both in transcription through
activation of TCF/LEF-binding sites and in adhesion through its binding to cadherins. We ﬁrst tested whether
Fbxo7 affected transcriptional activation using a TCF/LEF luciferase reporter, which is responsive to β-catenin,
in U2OS cells. We found that the overexpression of Fbxo7 increased transactivation from this reporter, and this
was dependent on the F-box domain (Figure 5D). We also show that inhibition of Gsk3β upon LiCl treatment
strongly activates the TCF/LEF reporter, and no further induction of reporter activity is seen with Fbxo7
expression, arguing for its effect being via Gsk3β inhibition (Supplementary Figure S4C). We also tested
whether Gsk3β localization was changed as a result of Fbxo7 expression, but no signiﬁcant differences were
observed by immunoﬂuorescence assays, neither when Fbxo7 was overexpressed nor when its levels were
reduced (Supplementary Figure S4D,E). Gsk3β levels were also not signiﬁcantly altered by Fbxo7 overexpression
(Supplementary Figure S4F). To determine if Fbxo7 affected Gsk3β activity, we utilized a GFP reporter with a
degron that is sensitive to levels of Gsk3β activity [37]. For comparison, a GFP reporter with alanine substitu-
tions of the Gsk3β phosphoacceptors in the degron was used. The co-expression of Fbxo7, but not the ΔF-box
mutant, with the GFP reporter signiﬁcantly increased the mean ﬂuorescence intensity of the cells compared
with vector only expressing cells, indicating a decrease in Gsk3β kinase activity (Figure 5E). Taken together,
these data argue for a repressive effect of SCFFbxo7 ubiquitination on Gsk3β activity.
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In the case of Tomm20, there was a signiﬁcant decrease in its endogenous levels when Fbxo7 was knocked
down constitutively or by transient transfection of siRNA (Figure 5C and Supplementary Figure S4B), suggest-
ing that Fbxo7 stabilizes Tomm20 levels. Conversely, a small and reproducible 50% increase was observed in
Figure 5. Analysis of ubiquitin chain linkages catalyzed on SCFFbxo7 substrates Gsk3β and Tomm20.
(A) UbiCRest analyses using DUBs for polyubiquitinated Gsk3β puriﬁed from cells (n = 2). The non-speciﬁc DUB (USP21)
cleaved all ubiquitin chains from polyubiquitinated Gsk3β, and K63-speciﬁc DUB, OTUD1, showed concentration-dependent
activity against polyubiquitinated protein. (B) Immunoprecipitation of Gsk3β from cells and detecting the presence of K63
polyubiquitin chains using a K63-speciﬁc antibody (n = 2). Asterisk indicates heavy or light chains. (C) Effect of reducing Fbxo7
expression on expression of Gsk3β and Tomm20. HEK293T cell lines expressing two independent shRNAs for Fbxo7 (Fbxo7
sh1 and sh2) or vector control were used. Immunoblotting with the indicated antibodies was performed and protein levels were
determined relative to GAPDH. The ratio of the densitometry value for each substrate relative to GAPDH is graphed (n = 3).
(D) U2OS cells were co-transfected with an empty luciferase vector (pTA-luc) or a β-catenin-responsive TCF/LEF luciferase
reporter, along with a Renilla luciferase reporter as a transfection control. Cells were also co-transfected with an empty vector
(vec), Fbxo7 or Fbxo7(ΔF-box). After 48 h, cells were harvested and luciferase expression was assayed in quintuplicate from
cell lysates using the Dual Glo kit according to the manufacturer’s instructions (Promega), and luciferase levels were
normalized to Renilla levels and expressed relative to pTA-luc control levels (n = 3). (E) U2OS cells were transfected with
MAPK-Gsk3β-GFP or MAPK-Gsk3βmut-GFP reporters with empty vector, Fbxo7 or Fbxo7(ΔF-box), and GFP expression was
determined by ﬂow cytometry. GFP mean ﬂuorescence intensity (MFI) was expressed as a percentage of
MAPK-Gsk3βmut-GFP levels (n = 6). (F) U2OS cells were co-transfected with Tomm20-HA and the indicated plasmids bearing
Fbxo7 WT or PD-associated mutant alleles, and immunoblots on total cell lysates were performed for the transfected proteins
as indicated, and GAPDH used as a loading control. ***P-value is <0.001, **P-value is <0.01.
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endogenous Tomm20 levels when Fbxo7 was overexpressed, (Supplementary Figure S4F). These data indicate a
direct correlation between endogenous Fbxo7 and Tomm20 expression levels. However, results in Figure 4G
argue that stabilization of Tomm20 occurred independently of Fbxo7 being part of an SCF complex. As can be
seen in Figure 4G, overexpression of WT Fbxo7 and the H1 mutant both caused increased Tomm20-HA levels
(Input, IB: HA, lanes 3 and 5), even though H1 does not recruit Skp1. These data suggest that the stabilization
of Tomm20 does not require ubiquitination by SCFFbxo7.
We also tested whether the mutants in Fbxo7 associated with early-onset PD affected the ubiquitination of
Tomm20 by co-transfecting cells with the mutant Fbxo7 alleles (T22M, R378G, and R498X) and Tomm20-HA
(Figure 5F). The presence the higher MW mono- and di-ubiquitinated Tomm20 were not altered by
co-transfection of mutant alleles of Fbxo7 when compared with WT Fbxo7. Importantly, as the T22M Fbxo7
mutant cannot bind to Parkin, these data strongly argue that the ubiquitination detected was not due to
Parkin-mediated ubiquitination, but rather mediated by Fbxo7. These data indicate that mutant Fbxo7 alleles
were capable of enhancing Tomm20 ubiquitination, and suggest that defects in Tomm20 ubiquitination do not
contribute to the aetiology of the Fbxo7 cases of early-onset PD.
Discussion
In a study of the Cullin interactome using MS and where the abundance of the cullin-associated proteins was
calculated based on peptide recovery, Fbxo7 was the ﬁfth most abundant F-box protein identiﬁed (behind
Skp2, Fbxl18, Fbxo21, and Fbxo22), suggesting that SCFFbxo7 is a stable, abundant E3 ligase in a modiﬁed 293
cell line [49]. In agreement with this prediction, we found that the puriﬁed SCFFbxo7 ligase from HEK293T
cells was indeed abundant, stable and robustly active when used for in vitro assays. A total of 338 unique pro-
teins, or about 3.6% of the proteins on the array, were deﬁned as putative substrates of SCFFbxo7 ubiquitination
using a cell-independent methodology to obtain a global view of its activity. Approximately 123 (36%) of the
Fbxo7 ubiquinome are listed as ubiquitinated proteins in either HEK293T and/or U2OS cells [50,51], with 17%
of this subset affected by treatment with a proteasomal inhibitor MG132. In comparison, the number of sub-
strates identiﬁed in the present study is about four times those for SCFFbxo25 and SMURF1 where 89 and 75
substrates, respectively, were identiﬁed using a similar experimental approach [33,41]. The substrates for
SCFFbxo7 do not overlap with these other screens, arguing for the speciﬁcity of these ligases in comparable set-
tings. We hypothesize that within speciﬁc cell types, SCFFbxo7 activity and the chain linkages assembled will be
reﬁned and dictated by the expression levels of Fbxo7, the abundance and potential PTM of its substrates, and
the E2 ligases with which it engages.
An enrichment analysis of KEGG pathways revealed that several proteins directly involved in the Wnt signal-
ing pathway, including Csnk1E, Gsk3β, Prickle2, and Nkd2, were ubiquitinated by SCFFbxo7 on the Protoarray®.
Gsk3β phosphorylates proteins like β-catenin, Snail, and Smad, which creates a degron for E3 ligases SCFβ-TRCP
Figure 5. Continued
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and SMURF1 that ubiquitinates them to promote their proteasomal degradation [52–55]. The deregulation of
this pathway is associated with several types of cancer [56,57]. In addition to its function in the Wnt pathway,
Gsk3β phosphorylates a large number of proteins located throughout the cell and is involved in many cellular
processes such as cell proliferation, differentiation, microtubule dynamics, cell cycle, and apoptosis [58]. With
such pleiotropic function, Gsk3β is linked with many different diseases including diabetes, cancer, Alzheimer’s
disease, osteoporosis, and cardiac hypertrophy, and also with PD [59]. Investigations into the role of Gsk3β in
PD have uncovered many associations including a high level of kinase activity within the striatum and also the
ﬁnding that a phosphorylated form of Gsk3β is found surrounding Lewy bodies, which may stem from the fact
that Gsk3β can directly phosphorylate α-synuclein [60–62]. Gsk3β is also an interesting therapeutic target, and
several small-molecule inhibitors have already been described [63]. We ﬁnd that SCFFbxo7 can ubiquitinate
Gsk3β and promote K63 linkages. Fbxo7 did not affect Gsk3β endogenous levels or localization, but instead
repressed its activity leading to increased expression of a Gsk3β-sensitive GFP reporter and increased β-catenin
transactivation in cells. Our data place Fbxo7 in the complex regulatory landscape of Gsk3β function and activ-
ity, and indicate that the consequences of Gsk3β ubiquitination by SCFFbxo7 warrant further investigation in the
context of neurodegenerative PD model systems.
Fbxo7 has a reported role in mitophagy through its direct association with two other PD associated proteins,
PINK1/PARK6 and Parkin/PARK2 [21]. Upon depolarization, Tomm20 is one of the mitochondrial proteins
that is ubiquitinated by Parkin [64,65]. Tomm20 is a core component of the mitochondrial translocase
complex, and its overexpression alone can promote mitophagy [44]. We demonstrate here that under normal
conditions, WT Fbxo7 and the mutant alleles of Fbxo7 stabilized its levels, which did not depend on SCF for-
mation, and promoted Tomm20 mono-, multi-mono-, or di-ubiquitination. The overexpression of human
Fbxo7, but not the PD-associated alleles, rescues the phenotypes of parkin loss in a Drosophila model of neuro-
degeneration [21]. However, the WT and mutant alleles tested have a similar ability to ubiquitinate Tomm20,
indicating that improper ubiquitination of Tomm20 by Fbxo7 is unlikely to be the pathological deﬁciency.
These included a T22M mutant of Fbxo7, which cannot recruit Parkin, indicating Parkin was not catalyzing
Tomm20 ubiquitination in these experiments. An enrichment analysis of the substrates by GO Cellular
Compartment revealed a further 29 mitochondrial proteins, which may indicate a more general role of Fbxo7
in mitochondrial biology, and suggests that Fbxo7 may affect other activities through ubiquitination of sub-
strates, like ATP5C1, CHCHD2, and MTIF3, mitochondrial translation initiation factor 3 (Supplementary
Table S5). We note that the only reported polymorphism within MTIF3, rs7669, has been reported to show a
signiﬁcant association with risk of PD [66], and CHCHD2 also has been reported to be associated with cases of
autosomal dominant PD [67–69]. These substrates indicate a connected network among the genes mutated in
familial PD data and are an area for future study.
In summary, we identiﬁed 338 new targets of SCFFbxo7 using a high-throughput, cell-independent proteomic
approach and validated Gsk3β and Tomm20 as new substrates, and argue against defective regulation of
Tomm20 by Fbxo7 as an underlying mechanism in PD. On the basis of our ﬁndings, we predict that Fbxo7
will impact on multiple biological functions, and this potentially explains why this F-box protein is of clinical
importance in pathologies affecting many different tissue and cell types. Our dataset opens new perspectives
and avenues for investigation in determining the role of SCFFbxo7 ligase activity in the biology of human
diseases, including PD and cancer.
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